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ABSTRACT
Introduction: During the last 4 decades, registration of patients with primary immunodeficiencies (PID) 
has played an essential role in different aspects of these diseases worldwide including epidemiological 
indexes, policymaking, quality controls of care/life, facilitation of genetic studies and clinical trials as 
well as improving our understanding about the natural history of the disease and the immune system 
function. However, due to the limitation of sustainable resources supporting these registries, incon-
sistency in diagnostic criteria and lack of molecular diagnosis as well as difficulties in the documenta-
tion and designing any universal platform, the global perspective of these diseases remains unclear.
Areas covered: Published and unpublished studies from January 1981 to June 2020 were systematically 
reviewed on PubMed, Web of Science and Scopus. Additionally, the reference list of all studies was 
hand-searched for additional studies. This effort identified a total of 104614 registered patients and 
suggests identification of at least 10590 additional PID patients, mainly from countries located in Asia 
and Africa. Molecular defects in genes known to cause PID were identified and reported in 13852 
(13.2% of all registered) patients.
Expert opinion: Although these data suggest some progress in the identification and documentation 
of PID patients worldwide, achieving the basic requirement for the global PID burden estimation and 
registration of undiagnosed patients will require more reinforcement of the progress, involving both 
improved diagnostic facilities and neonatal screening.
KEYWORDS
Primary immunodeficiencies; 
burden of disease; ethnicity; 
prevalence; molecular 
diagnosis
1. Introduction
Primary immunodeficiencies (PID) are described as heteroge-
neous diseases with a shortcoming in the development and 
function of the immune system [1,2]. PID patients usually 
suffer from more severe and repeated infections [3], however, 
dysregulation of immunity predisposes the immunodeficient 
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patients to lymphoproliferation, atopy, autoimmunity and 
malignancy [1,4]. Since the first report of PID in 1952, we 
have encountered an explosion of knowledge in this field 
with recognition of more than 400 genetic defects that are 
connected to even more PID phenotypes [1], that make this 
group of diseases an independent pursuit within biomedicine.
Presentation of PID varies from potentially benign forms 
such as IgA deficiency to catastrophic types such as severe 
combined immunodeficiency (SCID). Complex medical fea-
tures and the necessity for lifelong and resource-consuming 
treatments in many patients underscores the importance of 
qualified epidemiological data in decision making and PID 
management. Although epidemiological research in this field 
faces a variety of difficulties due to the novelty of PID and its 
rarity [5], national and international collaborations help to 
advance translational research and improve the management 
and therapeutic strategies [6,7].
Most of the prevalence estimations have been based on 
selected populations such as tertiary hospitals, or single-center 
registries. Reports from several PID registries in different coun-
tries show a prevalence of 1:8500 to 1:100000 for symptomatic 
patients [5,8–14]. However, it has been generally accepted 
that PID is under-diagnosed and under-reported. 
Furthermore, measurement of the burden of PID is restricted 
owing to insufficient recording and reporting. In 1981, the 
registration of patients was first advanced within countries 
initiated by Japan [15], followed by intracontinental registra-
tion efforts such as by the Latin American Society for 
Immunodeficiencies (LASID) in 1993 [16] and even global 
initiatives advanced by the Jeffrey Modell Foundation (JMF) 
in 2011 [17].
Although it has been suggested that obtaining incidence 
rates from local networks and national registries with proper 
data documentation could be a way to predict incidence for 
larger populations, this method cannot create a valid picture 
of PID in other populations as the prevalence of particular PID 
varies in different ethnic groups [18]. To consider this issue, 
several larger networks have been formed to collect the data 
from independent countries and diverse regions such as the 
European Society for Immunodeficiencies (ESID), LASID and 
The United States Immunodeficiency Network (USIDNET) data-
bases [16,19]. However, obvious discrepancies among different 
online sources and published documents create challenges in 
measuring accurate global disease burdens. This review is 
designed to systematically consider all available evidence 
regarding PID registries and present the frequencies of these 
diseases in 80 countries and all well-known international PID 
networks. The overarching objective is to provide deeper 
insights into the epidemiology of PID by comparing world-
wide the prevalence, clinical and molecular diagnoses, and 
predisposing factors in different populations.
2. Methods
Detailed methods, including search strategy for systematic 
review, study selection, data extraction and quality assessment 
are described in the Supplementary Method and Figure S1. 
The study was approved by the ethics committee of Tehran 
University of Medical Sciences, Tehran, Iran.
3. Results
3.1. Asia
A total of 15939 PID patients from 18 nationwide registries 
were surveyed in Asia (Table 1) representing a diverse distri-
bution of PID in these countries based on PID prevalence 
(Figure 1), parental consanguinity (Figure 2), proportions of 
PID categories (Figure 3), gender ratio (Figure 4) and genetic 
diagnosis (Figure 5). The first PID registry was reported in 
Japan, which included 497 patients [15] and the most recent 
data from Japan has been reported in 2011 by Ishimura et al., 
in which a total of 1240 patients have been registered with 
a prevalence of 2.3 per 100000 inhabitants. Predominantly 
antibody deficiencies (41.2%) were the most frequent type of 
PID, followed by congenital defects of phagocyte (18.5%) and 
other well-defined immunodeficiency syndromes (16%). 
Bruton’s tyrosine kinase (BTK) deficiency was the most preva-
lent genetic defect amongst Japanese PID patients. Common 
variable immunodeficiency (CVID) and selective IgA deficiency 
(SIgAD) comprise only 11% and 4% of the PID patients, respec-
tively [14].
Article highlights
● Globally, there are more than 6 million children under the age of 15 
years die annually despite substantial progress in vaccination, ade-
quate nutrition, exclusive breastfeeding, reduction of household air 
pollution, providing safe water and food and adequate sanitation and 
hygiene worldwide. Leading causes of death in children include 
severe infectious diseases (i.e. pneumonia and diarrhea) which 
could affect mainly those with underlying immune system defects. 
Although vaccines are available for some of the most deadly child-
hood diseases, such as measles, polio, diphtheria, tetanus, and per-
tussis, pneumonia due to Haemophilius influenzae type B and 
Streptococcus pneumonia and diarrhea due to rotavirus, they cannot 
protect immunodeficient children from illness and death.
● PIDs are a heterogeneous group of disorders, and no single assay at 
present will identify all forms of PID, necessitating a challenge of 
newborn screening paradigms. Therefore, there is no correct estima-
tion of the global PID prevalence in different regions and ethnicities.
● This is the first systematic review on PID patients’ registries world-
wide summarizing the differences in the distribution and properties 
of immune system disorders. The authors’ systematic review included 
104614 patients registered in 80 countries from five continents.
● The authors found that PID patients are at significant risk of mis-
diagnosis and misclassification in Asia and Africa, the continents with 
the highest report of childhood death. The findings provide impor-
tant new insights into the genetic diagnosis of diagnosed patients in 
different registries and entitlement to molecular approaches world-
wide and highlight the need to continue to promote global frame-
works for identification of monogenic causes as well as other 
molecular or environmental modifying factors.
● PID burden has been critically underestimated in policymaking and 
usually, it has been distributed in different categories– mainly infec-
tious diseases, diseases of the blood-forming organs, and neoplasms– 
because of an inaccurate diagnosis, multiple organ involvement, and 
different phenotypes. Governments, policymakers, and clinicians 
must work to develop and enforce measures for early diagnosis of 
PID, and promote access to appropriate management based on the 
type of the disease. Existing international frameworks must continue 
to implement correct clinical, immunological and genetic picture of 
the PID.
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Iran was the second country in Asia to report the national 
PID registry published in 2002 [25], with updated data 
reported in 2018 [4,26]. In total, 3056 PID patients were 
reported by the Iranian PID network centers thus describing 
the largest cohort of patients in Asia and the fifth-largest 
national cohort of patients globally. The prevalence of PID 
has been estimated to be around 3.9 per 100000 in the 
population. Predominantly antibody deficiencies (29.5%) and 
combined immunodeficiency (17.3%) were the most common 
PID subcategories. SCID was reported as the most frequent 
specific disorder (21.1%) followed by CVID (14.9%). Molecular 
diagnosis was achieved in 33.1% of registered patients in this 
highly consanguineous cohort (60.1%).
Wang et al. published the first registry of 201 Chinese PID 
patients emanating from a single center in 2011. During 
recent years, efforts of different centers from seven main cities 
in the mainland China registered 2487 patients (the second- 
largest PID cohort in Asia, estimated prevalence of 
<0.2:100000, 45.7% genetically diagnosed). Predominantly 
antibody deficiency disease was the leading PID type with 
27.9% of all patients. Agammaglobulinemia was the most 
common specific PID disorder and mutations in the BTK 
gene were the most common genetic defect identified in the 
Chinese PID population (29%) [27,28].
Kilik et al. in 2013 have reported registry data of 1435 immu-
nodeficient patients from Turkey [29]. However, updated data 
Figure 1. Distribution of primary immunodeficiency prevalence in the world based on the number of reported patients per 100000 individuals (Gray color represents 
countries without registry or without published report).
Figure 2. Distribution of parental consanguinity among different registries of patients with primary immunodeficiency in the world. (Gray color represents countries 
without registry or without appropriate report).
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from the country among 6 documenting centers represented 
1837 patients in the 2014 report of the ESID registry [2]. The 
most recent report, however, provided a more border national 
view on 6392 patients when the common category of PID was 
predominantly antibody deficiency which was found in 69.1% of 
cases followed by autoinflammatory disorders (8.6%). Of note, 
combined immunodeficiencies occupied only 5.7% of patients in 
this registry. SIgAD and isolated IgG subclass deficiency were 
found to be the most common disorders amongst predomi-
nantly antibody deficiencies. In this registry, delay in diagnosis 
was calculated around 26.9 months and the consanguinity rate 
among reported patients was 14.3% [29,30]. Although several 
PID genes have been discovered in this cohort there is no 
national report on molecular diagnosis rate [31].
Al-Saud et al. published a registry report from Saudi Arabia 
with 502 patients in 2015 and identified a prevalence of all 
PIDs of 7.2 in 100000 children. The most common PID was 
combined immunodeficiencies (59.7%), followed by predomi-
nantly antibody deficiencies (12.3%) and congenital defects of 
phagocytosis (9.4%). T-B-SCID was the most common com-
bined immunodeficiencies phenotype (17%). The genetic 
diagnosis was identified in 152 patients (30.2%) from this 
cohort in which consanguinity was observed in 75% [32,33].
Madkaikar et al. reported 159 PID cases from a tertiary care 
center in India in 2013 followed by a more recent report 
describing 778 registered patients. Frequencies of PIDs were 
as follows: diseases of immune dysregulation (23.1%), phago-
cytic defects (21.3%) and predominant antibody deficiency 
Figure 3. Proportion of predominant antibody deficiencies among different registries of patients with primary immunodeficiency in the world. (Gray color represents 
countries without registry or without appropriate report).
Figure 4. Proportion of male to female ratio among different registries of patients with primary immunodeficiency in the world. (Gray color represents countries 
without registry or without appropriate report).
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(17.1%), Among patients molecular diagnosis was observed in 
40.2% and parental consanguinity was recorded in 19.4% 
[34–36].
During the last decade, other Asian PID cohorts have been 
reported containing fewer patients each. Al-Herz et al. in 2019, 
published a registry report of 314 PID patients in Kuwait with 
the highest genetically solved rate of 69.1% with 78.0% pater-
nal consanguinity (prevalence of PID 20.2 in 100000, predomi-
nantly antibody immunodeficiency of 17.8%) [37–39]. In 2013, 
Ehlayel et al. have reported a single-center registry of 131 
pediatric PID patients from Qatar with the lowest number of 
classical PID diseases and only 23.7% predominant antibody 
deficiency (prevalence of PID of 1.1 per 100000 children, 
genetic diagnosis of 36.6%, parental consanguinity of 61.1%) 
[40]. Although a cohort from Hong Kong also reported 107 
genetically solved PID patients, the current number of patients 
from this national registry is not updated and spans back to 
2014 with 180 reported patients [41–43]. Rhim et al. have 
reported 152 PID patients from Korea up to 2012 with an 
estimated prevalence of 1.1 per 100000 children with the 
highest rate of males to females with PID in Asia (~3.6) [34]. 
Other registries were reported from Oman (140 patients with 
high proportion of patients with congenital defects of phago-
cyte 35%) [44], Taiwan (215 patients with 50.6% molecular 
diagnosis) [13], Malaysia (150 patients) [43,45], Thailand (67 
patients) [46], Jordan (53 patients) [47], Singapore (39 patients) 
[48], UAE (30 patients) [49] and Bangladesh (13 patients) [50].
3.2. Oceania
PID registries in Oceania have been published only from 
Australia and New Zealand. The first publication was specific 
to Australia with 534 reported cases in 1997 [9] and the most 
recent report included both Australia and New Zealand 
published by Kirkpatrick et al. including 1209 cases in 2007 
(Table 1, Figures 1–5). The prevalence of PID was estimated at 
5.6 per 100000 for Australia, 12.4 for the state of South 
Australia, and 4.9 for both Australia and New Zealand. The 
most frequent subcategory of PID was predominately anti-
body deficiency syndromes (77.4%), followed by combined 
immunodeficiency (8.9%), hereditary angioedema (4.5%), and 
defects of phagocyte function (32%). CVID was the most fre-
quent diagnosis (38.4%) of all patients and the genetic diag-
nosis was established in 223 patients (18.4%) [12].
3.3. Africa
As the highest estimation, 4509 patients have been recorded 
in Africa mainly from 7 countries (Table 1, Figures 1–5). 
Initially, South African investigators published a series of PID 
patients at a single children’s hospital in Cape Town. Patients 
had been diagnosed for 14 years (between 1983 and 1996). 
The most frequent disorder of 93 total patients was antibody 
deficiency (59%) and the delayed diagnosis was noted in 
majority of patients [51]. Later, in 2011, Naidoo et al. updated 
this data to span a period of 27 years from 1983 to 2009 with 
168 patients. Again, antibody deficiency predominated 
(50.6%) and the second most common disorder was combined 
immunodeficiency (25.0%). A family history of PID was 
observed in 11% of the patients and consanguinity was 
reported only in 1.1% of the cases. Molecular diagnoses were 
archived in 7.7% of the cohort [52].
In 2015, Mellouli et al published a Tunisian nationwide reg-
istry of 710 PID patients spanning 25-years, thus representing 
the largest national cohort of the continent. The observed pre-
valence was 4.3 per 100000 in the population. The frequency of 
combined immunodeficiency disorders was 28.6%, followed by 
congenital defects of phagocyte (25.4%) and other well-defined 
Figure 5. Proportion of molecular diagnosis among different registries of patients with primary immunodeficiency in the world. (Gray color represents countries 
without registry or without appropriate report).
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immunodeficiency syndromes (22.7%), and antibody deficiency 
disorders (17.7%). The consanguinity rate of parents was 58.2% 
and a genetic diagnosis was identified in 13.8% [53].
Egypt was the second country to establish a PID registry in 
Africa; Reda et al. published a single-center study of PID 
patients in 2009 with 64 patients. Antibody deficiency with 
35.9% of cases was reported as the most abundant group of 
PID and combined immunodeficiencies were the second com-
mon PID category (29.7%). Consanguinity was reported in 
62.5% and the diagnostic delay was 29.9 months [54]. 
Recently updated records from the Maghreb registry demon-
strated that the registered patients in the country have risen 
to 476 with 106 molecularly diagnosed patients (22.2%) 
[49,55].
The PID registry next to emerge in Africa was from Morocco; 
Bousfiha et al. reported 424 PID patients registered by 2014. The 
reported prevalence of PID was 0.81 in 100000 inhabitants. The 
most prevalent disorders were reported as follows: well-defined 
immunodeficiency syndromes (27.4%), antibody deficiencies 
(22.7%) and combined immunodeficiencies (20.6%). 
Furthermore, agammaglobulinemia accounted for the majority 
of antibody deficiencies patients (54.7%) and MHC class II defi-
ciency was reported in 41.2% of combined immunodeficiencies. 
Parental consanguinity was identified in 43.2% of cases and 
19.1% of patients had a positive family history [56]. Three recent 
additions to the Maghreb registry have released their prelimin-
ary reports on the PID patients in Algeria, Libya and Sudan with 
600, 106 and 72 patients, respectively [49].
3.4. Europe
In this section, registries of main PID disorders were collected 
from both published national registries of European countries 
(highest estimation of 40223 patients) and the ESID registry 
between 1993 and 2014 (Table 1, Figures 1–5). That showed 
the current total patients from the ESID registry were not 
queried as part of this evaluation and reliance was placed on 
that, which could be aggregated by a systematic review of 
publicly available information. The first report of a European 
national registry was that of Luzi, et al at in 1983 who 
described 797 registered patients in the Italian Registry for 
PIDs. The most prevalent PID entity was humoral defects and 
SIgAD (66.6%) was found as the most frequent disease, fol-
lowed by T-cell disorders (14.2%) [57]. More recently the num-
ber of Italian patients in the ESID registry has reached 1275 
[2,58], but this has not been reflected in other publications 
from this country with no general information regarding the 
genetic diagnosis of all PID patients [59,60].
The largest cohort in Europe has been reported from 
France with 5426 patients within the ESID registry [2,58]. In 
the latest report from the French PID study group from as 
2019, 6602 patients were registered (mainly children) in the 
National Reference Center of PID. In this study, the total con-
sanguinity was reported as 15% of all patients. The most 
common PIDs were predominantly B-cell deficiencies (42.8%) 
and T-cell deficiencies (17.4%), respectively. The most frequent 
PID diseases were CVID (22.8%) and the molecular diagnosis 
was established in 43.3% of cases [61,62].
Closely following France in magnitude, Shillitoe et al. 
reported 4758 registered patients from 2008 to 2018 in the 
United Kingdom PID Registry, suggesting a doubling of the 
size of cohort compared to previous ESID registry report in 
2014. Antibody disorders formed the largest group (59.6%) of 
registered patients. The most frequent diseases of PIDs were 
CVID (36.3%), hereditary angioedema (8%) and agammaglo-
bulinemia (5.4%). Consanguinity was reported at 2.9% and 
a genetic diagnosis was confirmed in 25.3% of the cohort 
[63–65]. Abuzakouk, et al at in 2005, registered separately 
115 patients from 1996 to 2003 within a national registry for 
PIDs in the Republic of Ireland (higher than those in the ESID 
registry 2014 with 107 patients). The most prevalent PID enti-
ties were immunoglobulin deficiencies (46%) and complement 
deficiencies (27.8%). The most common diseases were CVID 
(24.3%) followed by X-linked agammaglobulinemia (21.1%) 
and C1 inhibitor deficiencies (13.9%) [66].
In 2005 the Polish Working Group for Immunodeficiencies 
(PWGID) was established and in their first report in 2016, with 
4099 recognized PID patients in Poland, demonstrating 
a prevalence of 10.6 per 100,000 with a dominance of anti-
body deficiencies (70.2%) representing the largest cohort 
among Eastern European countries [67].
The next largest registry in Europe belongs to Germany. El- 
Helou, et al reported 2453 registered patients spaning 2004 to 
2019 in a national registry for PIDs [68], the current data within 
the ESID database, however, has presented to 1981 cases. In 
this national registry, consanguinity was reported in 8.0% of 
the total number of patients and antibody deficiencies formed 
the largest PID group (56.76%). The most frequent diseases of 
PIDs were CVID (29.6%), followed by hypogammaglobulinemia 
(13.5%) and the genetic diagnosis was achieved on 43.3% of 
patients [69].
Matamoros et al. reported 2030 registered patients in the 
Spanish national registry for PIDs from 1993 to 2001. 
According to the ESID registry, the number of reported 
patients has reached 2211 in 2014 [2,58]. The most prevalent 
category in this country was antibody disorders (69.1%) mainly 
due to SIgAD (36.9%) and CVID (19.9%) [18].
Sweden also reported 2727 registered patients in 2019 
(most notably with antibody deficiency and phagocytosis dis-
orders, 43.3% and 13.8% respectively) [70,71]; however, due to 
the inconsistency with the ESID registry, there are only 92 
patients included in the continent registry [63,64]. Similarly, 
other Nordic countries also reported their registries of PID 
patients separately from ESID registry including Iceland with 
66 patients (39.4% antibody deficiency, 33.3% genetic diag-
nosis, with the highest estimated prevalence of PID in the 
world ~18:100000) [72], Norway with 372 patients (50.8% anti-
body deficiency, 8.8% genetic diagnosis) [10,73], Denmark 
with 179 patients (100% antibody deficiency, 1.6% genetic 
diagnosis) [74] and Finland with 132 patients (100% antibody 
deficiency, although in the recent report they did not include 
previous Finish patients with other PID entities) [75].
Registries from Croatia (226 vs. 24 patients), Czech (518 vs. 
259 patients), Portugal (208 vs. 76 patients), Slovenia (272 vs. 
16 patients), Slovakia (227 vs. 63 patients), Estonia (99 vs. 42 
patients), Belarus (436 vs. 67 patients), Romania (222 vs. 11 
patients), Lithuania (172 vs. 8 patients), Hungary (730 vs. 404 
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patients), Austria (312 vs. 105 patients), Azerbaijan (100 vs. 0 
patients), Bulgaria (113 vs. 0 patients), and Israel (294 vs. 4 
patients) are not updated in the ESID database and therefore 
national publications were referred to for the most accurate 
estimation. In contrast, the ESID registry is the only source for 
extraction of nationally diagnosed PID patients in many 
Eastern European countries including Serbia (88 patients), 
Ukraine (33 patients), as well as the most updated data from 
Belgium (258 patients), Greece (202 patients), Russia (204 
patients), Switzerland (352 patients) and the Netherlands 
(743 patients) [2,58,76] for which it has been included in 
these analyses as such (Table 1).
3.5. North and South America
The first registry in the United States dates back in 1993 and the 
first report of this initiative was published in 2000 with only 368 
patients. Afterward, following the formation of United States 
Immunodeficiency Network (USIDNET) for developing 
a research consortium to advance research in the field of PID, 
the recent output from their online website presented in 2020 
described 5484 diagnosed patients (45.8% genetically diag-
nosed). The most common diseases of PIDs were CVID (35%), 
IgA deficiency (26%), IgG subclass deficiencies (9%) and SCID 
(9%) [77]. Moreover, based on the JMF Physician Education and 
Public Awareness Campaign (PEPAC) in 2018, 30,227 patients in 
the United States were identified with specific PIDs. The patients 
classified within 8 major PID groups where the most prevalent 
deficiencies were first humoral immunodeficiencies (57.1%) and 
syndromic cellular immunodeficiencies were second (15.6%) 
[78]. The same data source from PEPAC shows the data regis-
tered from Canada from where 3047 patients have been docu-
mented, although detailed data on the PID category and genetic 
diagnosis has not yet been published from this country [78].
In a parallel effort, the LASID was established in 1993 and 
their first report was published in 1998 with collected informa-
tion on a total of 1428 patients from eight countries [79,80]. 
They later have issued their second report in 2006 with 3321 
patients registered from 12 countries and their online evalua-
tions demonstrated that currently 18 countries are included 
with a total number of 8146 patients. It was reported that 
53.0% had predominantly antibody deficiency and 22.6% had 
other well-defined PID syndromes as the main disease cate-
gories of the region. Genetic diagnosis has been made in 
18.0% of the registered patients [16,81–85].
The main registered patients of the LASID are from four 
national registries with more than 1000 patients including 
Argentina, Brazil, Mexico and Colombia. Nestor et al reported 
1319 PID patients from Argentina in 2007 which has now risen 
to 2730 patients in the LASID database. Reported frequencies 
were as follows: humoral (69.5%), phagocyte (4.3%), cellular 
(3.94%) and complement defects (1.4%). Grumach et al. in 
1997 reported data on 166 PID patients over 15 years referred 
to as a national center in Brazil. Now with 1879 patients, this 
national cohort stands as the second largest of the region 
where predominantly antibody deficiencies (60.8%), T cell 
defects (4.9%), and phagocyte disorders (18.7%) are the main 
PID categories [86]. SIgAD was recorded in 25.1% and CVID in 
20.3% of patients within this registry [87]. Mexico had 1744 
patients (36.3% antibody deficiencies) and Colombia had 1073 
(46.2% antibody deficiencies) patients, each as of prominent 
countries of the LASID registry that report their outcomes 
separately [83,84]. Table 1 represents the PIDs epidemiologic 
indexes based on reported cases of national and international 
registers of North and South American countries with an 
estimated 42067 patients.
4. Discussion
Via systematic review, we considered all evidence of publicly 
available PID registries world-over based on national reports 
from 80 countries as well as all well-known international regis-
tries. We considered certain clinical parameters and back-
ground factors including frequency of specific PIDs, country- 
specific prevalence, and percentage of consanguinity. Reports 
from the PID databases of different countries provide an 
opportunity to understand regional features and epidemiol-
ogy of PID globally as well as identifying reasons for clinical 
and epidemiological variations on different continents. 
Moreover, through the current exercise, we can evaluate pre-
vious measures as well as the global report from JMF and 
highlight potential underestimation and underreporting in 
different regions [88].
Asia is the most populous continent with 48 countries, but 
only 18 of them (37.5%) have the reported data of PID regis-
tries. It is notable that nearly half of these countries have not 
established a national registry, but many do have published 
PID data from single large medical centers including Qatar, 
Oman, Korea, Thailand and India which make these data rela-
tively unreliable as prevalence estimates. However, this short-
coming to some extent may be overlooked in small and low 
population countries, but the global estimation of PID is chal-
lenged by these types of data originating from large countries 
such as China and India [89]. Despite limitations in data, the 
spectrum of the prevalence of PIDs varies from a low of 
0.08:100000 in Bangladesh to a high of 20.2:100000 in 
Kuwait. Collectively, Middle Eastern countries show higher 
PID prevalence than other countries from Eastern Asia prob-
ably due to higher percentages of parental consanguinity. 
There were also vast variations in the prevalence of individual 
PIDs throughout the continent. Predominantly antibody defi-
ciencies were the most frequent subcategory of PID in East 
Asian countries which is parallel to results of Australia [90], 
LASID [81] and ESID [11] databases, and also the JMF network 
(55%) [78], but this percentage was lower in the cohorts from 
the Middle East (Figure 3). Combined immunodeficiencies 
were the most common PID entity in Saudi Arabia (59.7%) 
and the second most prevalent group of PID in other Middle 
Eastern countries such as Iran [91], and Kuwait [92], which are 
all much higher than the ESID, LASID [81] and other Western 
registries [8,11,18,57], Far-East countries [14,27,45], and 
Australia [12]. This finding is likely explained by the consider-
able rate of the parental consanguinity which is reported from 
the Middle East [32,54,91,92] and related to a high rate of 
autosomal recessive forms of PIDs [93–96]. The latest JMF 
data describe 8022 patients from Asian countries and thus 
this global registry has a gap of 7917 patients from currently 
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reported national registries (Table 1) demonstrating what is 
likely to be the partial capture of that network [88].
Diagnostic delay, which is defined as the elapsed time 
between the onset of PID symptoms and the establishment 
of diagnosis, can reflect the awareness of PID among physi-
cians and the public. The lowest was reported in Iran with 
a median of 12 months and the highest was in Malaysia at 
3.78 years. There was also an increased male to female sex 
ratio in all registries, but it was greater than 2 in Thailand, 
Korea, Malaysia, China and Japan suggesting a greater preva-
lence of X-linked transmission (Figure 4). Asian countries 
report a 25.9% molecular diagnostic rate which is the highest 
globally and is mainly attributed to the Middle East countries 
(Table 1, Figure 5).
Oceania is comprised of Australasia, Melanesia, Micronesia 
and Polynesia and has a population of 43 million living in 15 
countries. Reporting of PID patients, however, is available 
only from 2 countries (13.2%). Although the regional report 
presented 1209 patients, the recent JMF global report 
described 1876 patients from this region indicating the 
need to update registry reported data from Oceania, prob-
ably with the inclusion of countries included in the JMF net-
work but otherwise not part of regional registries. Of note, 
Oceania has an appropriate percentage of genetic diagnosis 
compared to other continents with 11.8% of reported 
patients (Table 1) [88].
Africa accounts for near 15% of the global population [97], 
but of its 54 countries, only 7 (12.9%) have published registries 
of PID patients. Furthermore, only Tunis, Morocco and South 
Africa have established countrywide registries and thus there 
is not enough experience to establish a continent-wide land-
scape of PID for Africa [98]. The recent establishment of the 
Maghreb registry and African Society of Immunodeficiency 
(ASID), however, could change this condition in the near 
future [49,98,99]. The reported prevalence of PID in African 
countries seems to be underestimated due to the general lack 
of awareness and knowledge of immunodeficiencies, however, 
a comparison with the JMF global report in which there were 
only 1836 patients to the 4509 now reported patients in the 
Maghreb registry suggests progress is accelerating (Table 1) 
[88]. Only 5.5% of all reported patients demonstrated 
a molecular diagnosis, the lowest continental rate globally. 
However, in North African countries, the appearance of auto-
somal recessive forms of PID is more frequent and is likely 
a result of consanguinity (Figure 2). The pattern of PID in 
North Africa (mainly with higher percentages of combined 
immunodeficiency), however, is dissimilar from that identified 
in South Africa (Table 1, Figure 3), possibly owing to higher 
rates of endogamy, geographical alteration, as well as genetic 
differences. Moreover, differences can be the result of variable 
data collection methods and awareness of PIDs between 
African countries.
As of 2014 the ESID registry contained 19355 patients and 
represented the most robust initial effort in registration. The 
database, however, does not cover all 51 European countries 
(58.8%, mainly missing from Nordic countries), although the 
estimation of the 2019 database reaches 25023 cases (includ-
ing Turkish patients) [2,58] and 33503 cases on their online 
website [100]. The current systematic review, however, esti-
mates several missing patients in the registry from individual 
national reports (Table 1). Compared to the JMF global report 
with 40223 patients from Europe [88], a gap of over 6720 
patients is apparent and thus efforts to pursue and integrate 
data from the missing countries are pressing [69,76,101]. 
Adaptive immune deficiencies due to predominantly B-cell 
deficiencies encompass the main category of PIDs in Europe 
(Figure 3) [61]. Based upon the national registries of European 
countries, Iceland with its well documented universal medical 
system reported the highest prevalence of PIDs globally. This 
has been hypothesized to be due to a sparse population and 
a small denominator which might skew the comparison to 
larger nations [72]. However, all Nordic countries cover acces-
sible and universal healthcare, while they also have regional 
enrichment of rare variants due to previous ‘genetic bottle-
necks’. This has led to the enrichment of so-called founder 
mutations in various monogenic autosomal recessive genes 
[102,103]. Also, the legislation of most Nordic countries does 
not presently allow for data exchange with cross-border regis-
tries. This does not serve the needs of rare disease patients nor 
follow the principles behind European General Data Protection 
(GDPR). According to GDPR, personal data should be designed 
to serve mankind. The right to the protection of personal data 
is not absolute; it must be considered in relation to its function 
in society and be balanced against other fundamental rights 
(e.g. equity, freedom of science, social rights, the duty of the 
society to promote public health), following the principle of 
proportionality [104]. Comparison with other European coun-
tries suggests that on average 5:100000 is a reasonable esti-
mation for the PID prevalence in Europe as a whole 
[5,10,105,106].
Overall, among European countries included in the ESID 
database, CVID composed approximately 55% and was the 
most prevalent PIDs registered, whereas, in older studies per-
formed, SIgAD was more commonly reported. The proportion 
of CVID is lower in France than reported by national registries 
than in other European countries such as Germany and the 
UK. There was also a relatively low observed prevalence of 
PIDs in adults in France. For the five European countries that 
reported patient consanguinity, France had the highest with 
15% along with a concomitant increase of PIDs with an auto-
somal recessive inheritance pattern (Figure 2). In general, 
national European registries reported average consanguinity 
of 3.4%. Moreover, based on reported cases in the ESID data-
base performed by Gathmann, et al at 2011 [107] focused on 
eight countries including France, Spain, Turkey, United 
Kingdom, Germany, Italy, Poland and Netherlands consangui-
nity was reported in 8.8%, and 18.5% of patients were 
reported to be familial cases. Genetic diagnosis is only 15.5% 
of clinically diagnosed patients with Belarus leading (57.3% 
definite diagnosis) followed by Slovenia (57.0% definite diag-
nosis) and France (40.0% definite diagnosis, Figure 5). The 
discrepancy amongst European countries suggests substantive 
opportunity to more broadly advance genetic diagnosis in 
Europe [76].
Unlike prevalence estimations in many countries based 
upon their registry reports and diagnosed cases, in the 
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United States, PID epidemiological indices were estimated via 
a very large geographically and racially diverse population. 
The USIDNET provides one of the most updated and advanced 
platforms of evaluation of patients in the country, but a recent 
report from JMF showed that the participant centers in this 
database were incomplete (5484 vs. 30227, 24743 missing 
patients) [88,108]. Moreover, the JMF registry is the only one 
that covers PID in Canada, a country with 37 million inhabi-
tants and 3047 patients. In contrast, the estimates from Latin 
American countries via the LASID database are more consis-
tent with data presented in the JMF global report (8146 vs. 
8793; only 647 missing patients) [82,88]. Reports from colla-
borative LASID countries demonstrate that in Latin America 
the most frequent form of PID is predominantly antibody 
deficiency, but less frequently than that observed in North 
America. Other observed differences, however, such as high 
numbers of patients with CID and MHC class II deficiency in 
Costa Rica’s and Peru and DiGeorge syndrome in Chile require 
further evaluation (Table 1). The comparison of PID prevalence 
(5:100000 vs 2:100000) and genetic diagnostic percentages 
(45.8% vs.18.0%) between North American countries and 
Latin American countries emphasizes a requirement for in- 
depth efforts to improve the PID registration quantity and 
quality.
5. Expert opinion
While many PIDs can be easily diagnosed and have effective 
treatment options available, awareness of PIDs and their man-
agement is low amongst both physicians and the general 
public in many countries leaving numerous patients undiag-
nosed. The number of undiagnosed cases is not known, how-
ever, because there is no population-based screening process 
for PID except newborn screening for SCID in certain coun-
tries. However, in the present systematic approach as shown 
in Table 1, we estimated possible reported patients of 104614 
based on registry reports and diagnosed cases that represent 
at least 10590 missing patients compared to the JMF global 
report [88]. The Jeffrey Modell Centers Network (JMCN) con-
sists of 821 Expert Physicians at 379 institutions, in 294 cities, 
and 86 countries spanning 6 continents. The JMF registry 
compiles significant data received directly from these report-
ing Centers from around the world. Of note, the number of 
individual country registries included in the analysis for each 
region in this systematic review may not be the same as the 
number of countries included in the JMF registry for each 
region. Similarly, the specific countries reporting may vary as 
well. Still, this number based on registrations remains under-
estimated as if we simply calculated the incidence of SCID 
disorders using estimates form newborn screening (1:50000 
individuals in a non-consanguineous population [109]) there 
should be at least 1540000 SCID patients worldwide. Several 
studies attempted to estimate the total number of PID 
patients based on hospital and population-based measure-
ments [37]. The upper estimates suggest 6–8 million people 
may be living with a PID worldwide (based on US population 
and hospital prevalence [77,110]). It is also estimated that 
more than 700000 new PID patients might be diagnosed 
annually (based on US population incidence [111]). In line 
with the total number of patients we reported based on our 
systematic review, the majority of experts in the PID filed 
reported that unfortunately a large portion of PID patients 
(70–90%) remain undiagnosed and do not have access to 
appropriate treatment, even in countries with existing PID 
facilities (the National Institutes of Health [NIH] estimates 
that as a group, PID may affect 1–2% of the population) 
[37,112]. The main reasons for high rates of undiagnosed PID 
patients include a low level of awareness of symptoms of PID 
among physicians, failure to consider this diagnosis and differ-
ences in diagnostic capabilities and treatment of PIDs from 
country to country on different continents and even within 
the same region [113]. It should be noted that many PIDs can 
be diagnosed easily with two simple blood tests (whole blood 
counts and immunoglobulin levels which diagnose antibody 
deficiencies and classical immunodeficiencies with a severe 
lack of lymphocytes or granulocytes) [114]. Prompt PID diag-
nosis results in better use of health facilities, surveillance of 
the risk that PID patients can expose for society (e.g. reservoir 
of Poliovirus challenging the Polio Eradication program [115]) 
and has been demonstrated to result in lower healthcare costs 
overall [116].
Both this systematic review and the JMF global report are 
in agreement that antibody deficiency (51.9% vs. 45.1%, 
respectively) and combined immunodeficiency (11.8% vs. 
6.1%, respectively) are the most often reported PIDs in the 
world. The number of males affected by PID is slightly higher 
than females, according to both systematic review and JMF 
global report (1.5 vs. 1.3, respectively) representing the sig-
nificant role of X-linked PID disorders in all registries except 
the UK and Iceland (Table 1, Figure 4). Parental consanguinity 
was positive in 6.2% of patients which is less than current 
estimates of global populations in the world (20%) [117], 
indicating the low contribution and presence of established 
PID registries in the countries with consanguinity (Figure 2). 
Where present, however, parental consanguinity demonstrates 
the increased frequency of autosomal recessive PID. In total, 
13.2% of patients received a final molecular diagnosis demon-
strating the shifting landscape of PID globally (Figure 5). In an 
effort to increase the molecular identification of PID patients 
and significantly increase the genetic diagnostic rate, the JMF 
is about to embark on a global genetic sequencing initiative. 
Their current data on global gene defects associated with PID 
showed that the chromosome 22q11.2 deletion syndrome 
(5215 cases), MEFV deficiency (2835 cases) and ATM deficiency 
(2514 cases) are the most common genetic defects worldwide 
[88]. Collective information and reports on variants are impor-
tant for long-term therapeutic strategies based on countries or 
geographical regions. This initiative aims to provide accurate 
diagnoses, leading to appropriate management and treat-
ment, and ultimately improved patient outcomes and quality 
of life [118]. Recruitment strategies of PID patients in the 
national and continent based cohorts should be revised to 
detect quicker patients with multidisciplinary care for patients 
presenting different types of infectious or noninfectious com-
plications. Moreover sustainable funding should be provided 
for long-term maintenance of the currently available data-
bases (societies, registries and websites) and to support highly 
specialized therapies (e.g. JMF and RITA European research 
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network) [88,119]. Although current data presented cover 
registries only from 80 countries, the JMF report covers more 
than 86 countries demonstrating the higher potential for the 
registry which should be pursued to improve current under-
standing of PID and increase the chances for improved man-
agement. The global burden of PID is clearly underestimated 
and improved registration efforts could help in more accu-
rately estimating the burden of the disease and allowing for 
the allocation of appropriate resources for these complex 
heterogeneous genetic disorders.
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